4.5 Article

Reduced abundance of the E3 ubiquitin ligase E6AP contributes to decreased expression of the INK4/ARF locus in non-small cell lung cancer

期刊

SCIENCE SIGNALING
卷 10, 期 461, 页码 -

出版社

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scisignal.aaf8223

关键词

-

资金

  1. National Health and Medical Research Council (NHMRC) of Australia [NHMRC 1063389, 1026990]
  2. Cancer Council Victoria [1085154]
  3. Victorian Endowment for Science, Knowledge, and Innovation award
  4. Victorian Cancer Agency-Richard Pratt Fellowship [Pratt14002]

向作者/读者索取更多资源

The tumor suppressor p16(INK4a), one protein encoded by the INK4/ARF locus, is frequently absent in multiple cancers, including non-small cell lung cancer (NSCLC). Whereas increased methylation of the encoding gene (CDKN2A) accounts for its loss in a third of patients, no molecular explanation exists for the remainder. We unraveled an alternative mechanism for the silencing of the INK4/ARF locus involving the E3 ubiquitin ligase and transcriptional cofactor E6AP (also known as UBE3A). We found that the expression of three tumor suppressor genes encoded in the INK4/ARF locus (p15(INK4b), p16(INK4a), and p19(ARF)) was decreased in E6AP(-/-) mouse embryo fibroblasts. E6AP induced the expression of the INK4/ARF locus at the transcriptional level by inhibiting CDC6 transcription, a gene encoding a key repressor of the locus. Luciferase assays revealed that E6AP inhibited CDC6 expression by reducing its E2F1-dependent transcription. Chromatin immunoprecipitation analysis indicated that E6AP reduced the amount of E2F1 at the CDC6 promoter. In a subset of NSCLC samples, an E6AP-low/CDC6-high/p16(INK4a)-low protein abundance profile correlated with low methylation of the gene encoding p16(INK4a) (CDKN2A) and poor patient prognosis. These findings define a previously unrecognized tumor-suppressive role for E6AP in NSCLC, reveal an alternative silencing mechanism of the INK4/ARF locus, and reveal E6AP as a potential prognostic marker in NSCLC.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Pathology

The Ring Study: an international comparison of PD-L1 diagnostic assays and their interpretation in non-small cell lung cancer, head and neck squamous cell cancer and urothelial cancer

Sung-liang Yu, Yi-jing Hsiao, Wendy A. Cooper, Yoon-la Choi, A. L. E. J. A. N. D. R. O. Aviles-salas, Teh-ying Chou, R. E. N. A. T. A. Coudry, Grigory A. Raskin, Stephen B. Fox, Chao-cheng Huang, Yoon Kyung Jeon, Young-hyeh Ko, Wen-hui Ku, Ghee-young Kwon, C. O. N. N. U. L. L. Leslie, Mei-chun Lin, Pei-jen Lou, C. R. I. S. T. O. V. A. M. Scapulatempo-neto, Saulo Mendoza Ramirez, N. I. K. I. T. A. Savelov, Hyo-sup Shim, Cesar Octavio Lara Torres, Isabela Werneck Cunha, L. A. R. I. S. A. Zavalishina, Yan-ming Chen

Summary: This study assessed the performance of PD-L1 diagnostic assays in NSCLC, HNSCC, and UC. The results showed that the performance of Ventana SP263 and Dako 22C3 assays was comparable in NSCLC and HNSCC. However, in UC, the performance of Ventana SP263 assay was less reliable and may impact treatment decisions.

PATHOLOGY (2023)

Article Oncology

A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study

Lavinia Tan, Ben Tran, Jeanne Tie, Ben Markman, Sumi Ananda, Niall C. Tebbutt, Michael Michael, Emma Link, Stephen Q. Wong, Sushma Chandrashekar, Jerick Guinto, David Ritchie, Rachel Koldej, Benjamin J. Solomon, Grant A. McArthur, Rodney J. Hicks, Peter Gibbs, Sarah-Jane Dawson, Jayesh Desai

Summary: BRAF V600E mutant metastatic colorectal cancer is a significant clinical problem. Combination therapy with vemurafenib and small-molecule EGFR inhibitors has shown effectiveness in pre-clinical studies, but clinical investigation is lacking.

CLINICAL CANCER RESEARCH (2023)

Review Cell Biology

Survey of recurrent diagnostic challenges in breast phyllodes tumours

Benjamin Yongcheng Tan, Stephen B. Fox, Sunil R. Lakhani, Puay Hoon Tan

Summary: Grading of breast phyllodes tumors (PTs) varies due to differences in weighting of grading criteria by pathologists. Key diagnostic criteria include increased stromal cellularity, stromal overgrowth, increased stromal mitoses, stromal atypia, stromal fronding, irregular tumor borders, and/or lesional heterogeneity. Clinical and radiological findings, as well as age, also play important roles in determining the diagnosis.

HISTOPATHOLOGY (2023)

Review Cell Biology

Identifying recurrences and metastasis after ductal carcinoma in situ (DCIS) of the breast

Ruwangi Udayasiri, Tongtong Luo, Kylie L. Gorringe, Stephen B. Fox

Summary: Ductal carcinoma in situ (DCIS) is a non-invasive breast tumor with the potential to progress to invasive ductal carcinoma (IDC). The current inability to accurately predict the invasive potential of DCIS leads to both over-treatment and under-treatment in patients. Better understanding of the molecular features of DCIS could improve treatment decision-making and avoid unnecessary side-effects. This review summarizes the current knowledge of DCIS and discusses future research directions.

HISTOPATHOLOGY (2023)

Article Cell Biology

Phyllodes tumour evidence gaps mapped from the 5th edition of the WHO classification of tumours of the breast

Nur Diyana Md Nasir, Valerie C. Y. Koh, Ian A. Cree, Blanca I. I. Ruiz, Javier Del Aguila, Subasri Armon, Stephen B. Fox, Sunil R. Lakhani, Puay Hoon Tan

Summary: In this study, an evidence gap map (EGM) was developed based on the literature cited in the PT chapter of the breast WCT. The EGM revealed a lack of high-level evidence citations and an uneven distribution of references. Future work is needed to bridge evidence gaps and broaden citations.

HISTOPATHOLOGY (2023)

Editorial Material Oncology

Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer

Benjamin J. Solomon, Todd M. Bauer, Tony S. K. Mok, Geoffrey Liu, Julien Mazieres, Filippo de Marinis, Yasushi Goto, Dong-Wan Kim, Yi-Long Wu, Jacek Jassem, Froylan Lopez Lopez, Ross A. Soo, Alice T. Shaw, Anna Polli, Rossella Messina, Laura Iadeluca, Francesca Toffalorio, Enriqueta Felip

FUTURE ONCOLOGY (2023)

Editorial Material Oncology

Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer

Trudy C. Wu, Annalise Stube, Carol Felix, Denise Oseguera, Tahmineh Romero, Jonathan Goldman, Edward B. Garon, Jay M. Lee, John Glaspy, Aaron E. Lisberg, Chad G. Rusthoven, D. Ross Camidge, Shankar Siva, Benjamin Solomon, Alan Lee, Stephen E. Tenn, Narek Shaverdian, Michael L. Steinberg, Ann C. Raldow, Percy Lee

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2023)

Letter Oncology

Response to Letter to the Editor From Binghao Zhao et al

Nicolas Girard, Marina C. Garassino, Benjamin Solomon

JOURNAL OF THORACIC ONCOLOGY (2023)

Letter Oncology

About Clinical Significance of Lung-RADS Category 3 Lesions

Nicolas Girard, Marina C. Garassino, Benjamin Solomon

JOURNAL OF THORACIC ONCOLOGY (2023)

Article Oncology

Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC

Ross A. Soo, Jean-Francois Martini, Anthonie J. van der Wekken, Shunsuke Teraoka, Roberto Ferrara, Alice T. Shaw, Deborah Shepard, Anna Maria Calella, Anna Polli, Francesca Toffalorio, Pascale Tomasini, Chao-Hua Chiu, Dariusz M. Kowalski, Hye Ryun Kim, Benjamin J. Solomon

Summary: In treatment-naive patients with advanced ALK-positive NSCLC, ctDNA can be used as a biomarker to predict the efficacy of lorlatinib treatment.

JOURNAL OF THORACIC ONCOLOGY (2023)

Article Medicine, General & Internal

Sotorasib versus docetaxel for previously treated non-small- cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

Adrianus Johannes de Langen, Melissa L. Johnson, Julien Mazieres, Anne -Marie C. Dingemans, Giannis Mountzios, Miklos Pless, Jurgen Wolf, Martin Schuler, Herve Lena, Ferdinandos Skoulidis, Yasuto Yoneshima, Sang-We Kim, Helena Linardou, Silvia Novello, Anthonie J. van der Wekken, Yuanbin Chen, Solange Peters, Enriqueta Felip, Benjamin J. Solomon, Suresh S. Ramalingam, Christophe Dooms, Colin R. Lindsay, Carlos Gil Ferreira, Normand Blais, Cynthia C. Obiozor, Yang Wang, Bhakti Mehta, Tracy Varrieur, Gataree Ngarmchamnanrith, Bjorn Stollenwerk, David Waterhouse, Luis Paz-Ares

Summary: This study compared the efficacy and safety of Sotorasib with standard-of-care treatment in patients with non-small-cell lung cancer (NSCLC) with the KRASG12C mutation. The results showed that compared to docetaxel, Sotorasib significantly increased progression-free survival and had a more favorable safety profile.

LANCET (2023)

Review Oncology

Optimal first-line treatment for metastatic ALK plus non-small cell lung cancer-a narrative review

Grace Chazan, Benjamin J. Solomon

Summary: First-line treatment options for patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbour anaplastic lymphoma kinase (ALK) gene rearrangements have evolved rapidly. Although newer generation ALK inhibitors have demonstrated superiority to crizotinib, head-to-head clinical trials comparing these inhibitors are lacking. Decisions on optimal first-line treatment must be based on analysis of relevant trials and consideration of various factors.

TRANSLATIONAL LUNG CANCER RESEARCH (2023)

Article Genetics & Heredity

Graft-Derived Cell-Free DNA Quantification following Liver Transplantation Using Tissue-Specific DNA Methylation and Donor-Specific Genotyping Techniques: An Orthogonal Comparison Study

Daniel R. A. Cox, Tess McClure, Fan Zhang, Boris Ka Leong Wong, Adam Testro, Su Kah Goh, Vijayaragavan Muralidharan, Alexander Dobrovic

Summary: Both graft-specific DNA methylation analysis and donor-recipient genotyping techniques successfully quantified gdcfDNA in patients post-liver transplantation, with significant correlation. While the two techniques performed similarly, gdcfDNA monitoring based on graft-specific DNA methylation patterns in cfDNA offers greater practical advantages and enhances the potential for clinical translation.

EPIGENOMES (2023)

Article Cell Biology

Establishing the Link between X-Chromosome Aberrations and TP53 Status, with Breast Cancer Patient Outcomes

Franco Caramia, Terence P. Speed, Hui Shen, Ygal Haupt, Sue Haupt

Summary: This study found an association between dysregulation of X-chromosome inactivation and survival rate in breast cancer patients, and identified prognostic gene expression features related to chromosome abnormalities, providing new insights into female cancer risks.
Review Cell Biology

Spatial transcriptomics and the anatomical pathologist: Molecular meets morphology

Jia-Min B. Pang, David J. Byrne, Alice R. T. Bergin, Franco Caramia, Sherene Loi, Kylie L. Gorringe, Stephen B. Fox

Summary: In recent years, molecular findings have been incorporated into routine diagnostic practice of anatomical pathology, revolutionizing the field. Spatial transcriptomics, a group of technologies that provide transcriptome-wide expression profiling while preserving spatial origin of the data, allows analysis of highly specific areas within a tissue section and correlation of expression data with morphology, tissue type, and location relative to other structures. Some spatial transcriptomics methods are now compatible with formalin-fixed paraffin-embedded tissue (FFPE), potentially leading to their incorporation in routine anatomical pathology practice.

HISTOPATHOLOGY (2023)

暂无数据